LEVERKUSEN (dpa-AFX) - Bayer AG (BAYRY) announced on Thursday that its
subsidiary, Asklepios BioPharmaceutical, Inc., also known as AskBio, has
received Fast Track Designation from the FDA for the AB-1002 also known as
NAN-101 program, aimed at treating patients with advanced congestive heart
failure or CHF.

AskBio is currently recruiting participants for the Phase II Gene PHosphatase
Inhibition Therapy or GenePHIT trial of AB-1002 intended for treating CHF.

The primary goal of the Phase II adaptive trial of GenePHIT is to evaluate the
safety and efficacy of AB-1002 through a single administration using antegrade
intracoronary artery infusion in male and female individuals aged over 18 with
non-ischemic cardiomyopathy and New York Heart Association Class III heart
failure symptoms.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX